Clinical Trials
2 trialsNCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT01697514 2013-08-27
A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
Eli Lilly and Company
Phase 1 Withdrawn